Cardiovascular Clinical Trialists (CVCT) Forum ? Paris 2012 : National guideline implementation and national registries.

Title : Cardiovascular Clinical Trialists (CVCT) Forum ? Paris 2012 : National guideline implementation and national registries? NICESpeaker: Suzanna HARDMAN,London,GBR? German CHF registry: REFLECT ?HFSpeaker: Carsten TSCHOEPE,Berlin,GER? Eurobservational,the ESC Heart failure RegistrySpeaker: Aldo MAGGIONI,Florence,ITAAbstract : Multidisciplinary expert workshop: achievements,challenges and barriers to implementations of the ESC 2012 chronic heart failureEurobservational Research Program,the ESC Heart Failure Long Term RegistryChronic Heart Failure (HF) is associated with a high burden of mortality and morbidity,reduced quality of life,and increasing healthcare costs in both US and Europe. Evidence-based medicine represents the most effective means of ensuring that patients receive high-quality care and appropriate pharmacological/non-pharmacological management. With the increased prevalence of chronic HF,there is a concomitant increase in the number of related hospitalizations and,as chronic HF progresses,the risk of acute exacerbation increases. Acute HF is a complex,heterogeneous,clinical syndrome characterized by a rapid onset of signs and symptoms secondary to abnormal cardiac function,and it is often life threatening,requiring urgent therapy. In the United States,a primary diagnosis of acute HF accounts for more than one million hospitalizations each year,with similar numbers suggested for Europe. Despite significant advances in diagnosis and therapy obtained over the past 20 years,patients with HF,specifically those with acute HF,continue to have a poor long-term prognosis. Clinical destabilizations leading to hospitalization are associated with hemodynamic and neuro?hormonal alterations,which can contribute to progressive ventricular dysfunction and dilation,mitral regurgitation,increased wall stress,and progressive myocyte loss as a result of apoptosis and necrosis. Registries and surveys have been conducted in patients with either chronic HF or acute HF but a description of the whole clinical history of patients with HF,including the acute episodes and the consequent changes in clinical conditions and in the management strategies are not available. A registry able to capture all the relevant clinical information of patients with HF,including their acute episodes of decompensation,will enable us to improve our knowledge on epidemiology and outcomes of real world patients with this clinical condition. Further,specific questions of high clinical relevance could be answered using the information collected in the Registry. The ESC-HF Long-term Registry is a prospective,multicentre,observational study of patients presenting to Cardiology Centres in European countries. Site selection in each participating country will target a sample of hospitals of different levels of complexity from which patients will be recruited,focusing on capturing a broad spectrum of cardiology and HF specialty units regularly following outpatients with HF and admitting patients with acute,preexisting or new onset HF in order to build-up a network of centres representative of European reality. Up to the end of October 2012,more than 12,500 patients have been enrolled by 27 ESC countries.L'auteur n'a pas transmis de conflit d'intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum ? Paris 2012 Multidisciplinary expert workshop : achievements challenges and barriers to implantation of the ESC 2012 chronic heart failure guidelines.Chairpersons: Alain COHEN-SOLAL,Paris,FRA - Adrian VOORS,Groningen,NEDBackground: The ESC-HFA chronic and acute heart failure guidelines have recently been published. However,the challenge for guidelines does not cease with a consensus document. Practical implementation is the critical step in establishing higher standards of care for individual patients. Improved guideline uptake is not only an index of better standards but a validation of the process of guideline production.Improving consensus between guidelines is also important,differences in recommendations may act as a barrier to guideline. The NICE CHF guidance was updated in 2010,and it is not likely to be revised in short term.Practice differs from the guideline recommendations. Registries suggest differences in guideline interpretation and treatment/management of CHF between different stakeholders. Similarities and differences exist between GPs and hospital physicians' approaches to management of CHF. One important issue that is not covered by the current guidelines is the class effect issue. Canadian and Australian CHF guideline and 2010 NICE guideline name eplerenone as preferred drug in heart failure,ESC mentions only mineralocorticoid receptor antagonists (MRAs.) as a class.How to interpret compound vs. class effects while following guideline recommendations is an important issue.Cost-effectiveness is a key not only to the content of guidelines but also in the assessment of implementation. Limits on healthcare resources mandate that resource-allocation decisions be guided by considerations of cost in relation to expected benefits. In cost-effectiveness analysis,the ratio of net healthcare costs to net health benefits provides an index by which priorities may be set.Aims: This multidisciplinary consensus workshop aims at discussing CHF guideline implementation issues and the consequences on defining the place of MRA/eplerenone in management of CHF.Réalisation,production : Canal U/3S et CERIMESKeyword : Cardiovascular Clinical Trialists,Paris,2012,Cardiovascular prevention,ESC-HFA,eplerenone

Disciplines : Sciences médicales. Médecine
Mots-clés : Cardiovascular Clinical Trialists,Paris,2012,Cardiovascular prevention,ESC-HFA,eplerenone
Type de document : image en mouvement
Type de ressource : lecture
Niveau : higher education,formation continue
Auteurs ou éditeurs : Aldo MAGGIONI